BCL2 and cancer: However, treatment with CAR T cells produces nonnegligible toxicities, as cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome, which limits its application.30 Also, several anti-cancer agents that targeting NF-κB and BCL-2 have been investigated in DLBCL.